KalVista jumps as Italy’s Chiesi to acquire it for $1.9 bln

Kalvista Pharmaceuticals

29/04/2026 13:03

** Shares of biotech firm KalVista Pharmaceuticals KALV.O jump 38.6% to $26.66 premarket

** Co says Italy’s Chiesi Group will buy KalVista in a $1.9 billion deal, including debt, paying $27 per share in cash.

** The offer implies a 36% premium to KalVista’s average share price over the past month, co says

** Says deal gives Chiesi control of Ekterly, an oral, on‑demand drug for hereditary angioedema, a rare genetic condition that causes sudden, painful swelling attacks

** Co says the drug is approved in the U.S., Europe and Japan, and recorded strong early sales after its U.S. launch in July 2025

** Says the transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and customary conditions

** As of last close, stock up ~19% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))